Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: Preliminary results

Nuclear Medicine Communications

Volumn 34, Issue 8, 2013, Pages 727-732

  Demirci, Emre ^a   Ocak, Meltem ^a   Kabasakal, Levent ^a   Araman, Ahmet ^a   Ozsoy, Yildiz ^a   Kanmaz, Bedii ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ga 68 DOTA LAN; Ga 68 DOTA TATE; Neuroendocrine tumour; Octreotide; Somatostatin receptor

Indexed keywords

ANGIOPEPTIN; CONTRAST MEDIUM; GALLIUM 68; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TETRAXETAN; TETRAXETAN LANREOTIDE GA 68; TETRAXETAN OCTREOTIDE[3 TYROSINE] GA 68; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE LESION; BONE MARROW; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIGESTIVE SYSTEM INJURY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIVER INJURY; MALE; MEDIASTINUM; MENINGIOMA; NEUROENDOCRINE TUMOR; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879964266     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328362cca6     Document Type: Article

References (21)

1. Schaer JC,Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70:530-537.
2. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42:220-225.
3. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17:R53-R73.
4. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792-795.
5. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140:5136-5148.
6. Virgolini I, Szilvasy I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. In-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39:1928-1936.
7. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
8. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of In- 111-DOTA-DPhe-Tyr3-octreotide and In-111-DOTA-Lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med 2006; 33:532-540.
9. Srirajkanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of Ga-68 DOTATATE in patients with neuroendocrine tumors and negative or equivocal findings on In-111 DTPA octreotide scintigraphy. J Nucl Med 2010; 51:875-882.
10. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. Ga-68 DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with In-111 DTPA octreotide (OctreoScan). Mol Imaging Biol 2011; 13:583-593.
11. Frilling A, Sotiropoulos C, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of Ga-68 DOTATOC positron emission tomography/computed tomography on multimodal management of patients with neuroendocrine tumors. Ann Surg 2010; 252:850-856.
12. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: Ga-68 DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50:1214-1221.
13. Ambrossini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. Ga-68 DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010; 51:669-673.
14. Pettino C, Sarnelli A, Donna MD, Civollani S, Nanni C, Montini G, et al. Da-68-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 51:72-79.
15. Traub-Weidinger T, Guggenberg EV, Dobrozemsky G, Kendler D, Eisterer W, Bale R, et al. Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 2010; 54:52-60.
16. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of Ga-68 labelled peptides. Nucl Med Commun 2007; 28:870-875.
17. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. In-111-pentetrotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008; 26:963-970.
18. Campana D, Ambrossini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of Ga-68 DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51:353-359.
19. Miederer M, Seidl S, Buck A, Scheidhauer K,Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in Ga-68-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:48-52.
20. Kulaksiz H, Eissele R, Roessler D, Schulz S, Höllt V, Cetin Y, Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002; 50:52-60.
21. Nasir A, Stridsberg M, Strosberg J, Su PH, Livingston S, Malik HA, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control 2006; 13:52-60.